Inversago Pharma - Peripheral CB1 Blockade

Inversago Pharma Inc. is focused on the development of peripherally-acting CB1 receptor (CB1) inverse agonists for the treatment of diabetic nephropathy, NASH, type 1 diabetes and Prader-Willi Syndrome. While previous generation of centrally-acting CB1 inhibitors presented safety concerns, the therapeutic relevance of peripheral CB1 pathway is still strongly supported by comprehensive scientific evidence and  remains to be fully exploited. CB1 receptor world expert Dr George Kunos from US NIH has extensively demonstrated that peripherally-acting CB1 blockade provides an equivalent therapeutic potential to treat metabolic conditions such as obesity/NASH/T2D and fibrosis (liver and lung), without targeting central CB1 receptors.